We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Adaptable Lateral Flow Test Reader Being Promoted at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
A lateral flow test reader for either existing assays or for user-designed tests will be highlighted at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Abingdon Health (York, United Kingdom) will be highlighting its [U.S.] Food and Drug Administration registered and CE marked lateral flow reader, the ADxLR5, in Booth 3838 at the Philadelphia meeting.

The next generation ADxLR5 Lateral Flow Assay reader incorporates a 10.1-inch touch screen with graphical user interface and icon driven software. More...
The sample draw with interchangeable inserts allows for the reading of a wide range of devices and assays. Connectivity is via two USB ports, Ethernet connection, or WiFi.

The ADxLR5 reader complements Abingdon Health's Seralite – FLC (free light chain) rapid test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories with results available in about 10 minutes rather than days or weeks.

In addition, The ADxLR5 is fully customizable for user-designed fluorescence or colorimetric tests and is compatible with most formats of cassettes and test strips. The instrument includes touchscreen PC software to augment flexible test system development.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Abingdon Health

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.